论文部分内容阅读
目的探讨前列腺癌组织中结肠癌转移相关基因1(MACC1)及肝细胞生长因子受体(c-met)蛋白的表达及临床意义。方法应用免疫组化方法检测76例前列腺癌组织和16例前列腺增生组织中MACC1及c-met蛋白的表达情况。结果前列腺癌组织中MACC1蛋白阳性率为59.2%,显著高于前列腺增生组织(18.8%),(χ2=8.671,P=0.003);c-met蛋白在前列腺癌组织中阳性率64.5%,显著高于前列腺增生组织(31.2%),(χ2=6.018,P=0.014);随访结果提示MACC1和c-met阳性患者生存率显著低于阴性患者,(χ2=5.480,P=0.019;χ2=14.826,P<0.001);MACC1与c-met蛋白呈正相关。结论 MACC1及c-met蛋白表达增高与前列腺癌的临床分期、病理分级、患者预后密切相关。联合检测MACC1及c-met蛋白可以作为反映前列腺癌的生物学行为的客观指标,有助于判断患者预后。
Objective To investigate the expression and clinical significance of colon cancer metastasis associated gene 1 (MACC1) and hepatocyte growth factor receptor (c-met) in prostate cancer. Methods Immunohistochemistry was used to detect the expression of MACC1 and c-met protein in 76 cases of prostate cancer and 16 cases of benign prostatic hyperplasia. Results The positive rate of MACC1 protein in prostate cancer was 59.2%, significantly higher than that in benign prostatic hyperplasia (18.8%) (χ2 = 8.671, P = 0.003). The positive rate of c-met protein in prostate cancer was 64.5% (Χ2 = 6.018, P = 0.014). The follow-up results showed that the survival rates of MACC1 and c-met positive patients were significantly lower than those of negative patients (χ2 = 5.480, P = 0.019; P <0.001). There was a positive correlation between MACC1 and c-met protein. Conclusion The increased expression of MACC1 and c-met protein is closely related to the clinical stage, pathological grade and prognosis of patients with prostate cancer. Joint detection of MACC1 and c-met protein can be used as an objective indicator of biological behavior of prostate cancer, help to determine the prognosis of patients.